文献速递冠心病血脂与心血管预防

糖尿病相关因素与替格瑞洛联合阿司匹林在THEMIS及THEMIS-PCI试验中的效应

Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

基于THEMIS(n=19,220)和THEMIS-PCI(n=11,154)的事后分析,在2型糖尿病(中位病程10.0年,HbA1c 7.1%)合并稳定冠心病且无既往心梗或卒中的患者中,替格瑞洛联合阿司匹林较安慰剂联合阿司匹林在THEMIS-PCI中净临床获益一致,但在整体THEMIS人群中未一致出现。

要点

  • 替格瑞洛联合阿司匹林在THEMIS-PCI中净临床获益一致,整体THEMIS人群未一致。
  • 3点MACE发生率随糖尿病病程和HbA1c升高而增加。
  • 大出血发生率不随糖尿病病程或HbA1c变化,替格瑞洛在各亚组均相似增加大出血风险。

核心结论

  • 在THEMIS-PCI中,替格瑞洛联合阿司匹林在糖尿病相关因素各亚组中普遍产生有利的净临床获益,但在整体THEMIS人群中未一致出现。

研究设计与样本

  • THEMIS(n=19,220)及其预先设定的THEMIS-PCI(n=11,154)子分析的事后分析,比较替格瑞洛联合阿司匹林与安慰剂联合阿司匹林。
  • 研究对象为2型糖尿病(中位病程10.0年,HbA1c 7.1%)合并稳定冠心病且无既往心肌梗死或卒中的患者。

主要发现

  • 在THEMIS中,3点MACE发生率随糖尿病病程增加(≤5年6.7%,>20年11.1%),也随HbA1c升高(≤6.0% 6.4%,>10.0% 11.8%)。
  • 替格瑞洛联合阿司匹林对3点MACE的相对获益在各亚组间大体一致(HR 0.90;p=0.04)。
  • 大出血事件率(总体1.6%)不随糖尿病病程或HbA1c变化,替格瑞洛在各亚组均相似增加大出血风险(HR 2.32;p<0.001)。
  • 替格瑞洛联合阿司匹林的疗效和安全性不因基线降糖治疗而异。
  • 在THEMIS-PCI中,替格瑞洛在糖尿病病程、HbA1c和降糖药物各亚组中普遍产生有利的净临床获益;在THEMIS中未一致出现。

临床怎么用

  • 对于合并稳定冠心病且无既往心梗或卒中的2型糖尿病患者,若曾有PCI史,替格瑞洛联合阿司匹林可能带来一致的净临床获益。
  • 在整体THEMIS人群中,替格瑞洛联合阿司匹林的净临床获益未一致出现,临床决策需结合患者PCI史等特征个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: THEMIS (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study) (n = 19,220) and its pre-specified THEMIS-PCI (The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study-Percutaneous Coronary Intervention) (n = 11,154) subanalysis showed, in individuals with type 2 diabetes mellitus (median duration 10.0 years; HbA1c 7.1%) and stable coronary artery disease without prior myocardial infarction (MI) or stroke, that ticagrelor plus aspirin (compared with placebo plus aspirin) produced a favorable net clinical benefit (composite of all-cause mortality, MI, stroke, fatal bleeding, and intracranial bleeding) if the patients had a previous percutaneous coronary intervention. OBJECTIVES: In these post hoc analyses, the authors examined whether the primary efficacy outcome (cardiovascular death, MI, stroke: 3-point major adverse cardiovascular events [MACE]), primary safety outcome (Thrombolysis In Myocardial Infarction-defined major bleeding) and net clinical benefit varied with diabetes-related factors. METHODS: Outcomes were analyzed across baseline diabetes duration, HbA1c, and antihyperglycemic medications. RESULTS: In THEMIS, the incidence of 3-point MACE increased with diabetes duration (6.7% for ≤5 years, 11.1% for >20 years) and HbA1c (6.4% for ≤6.0%, 11.8% for >10.0%). The relative benefits of ticagrelor plus aspirin on 3-point MACE reduction (hazard ratio [HR]: 0.90; p = 0.04) were generally consistent across subgroups. Major bleeding event rate (overall: 1.6%) did not vary by diabetes duration or HbA1c and was increased similarly by ticagrelor across all subgroups (HR: 2.32; p < 0.001). These findings were mirrored in THEMIS-PCI. The efficacy and safety of ticagrelor plus aspirin did not differ by baseline antihyperglycemic therapy. In THEMIS-PCI, but not THEMIS, ticagrelor generally produced favorable net clinical benefit across diabetes duration, HbA1c, and antihyperglycemic medications. CONCLUSION: Ticagrelor plus aspirin yielded generally consistent and favorable net clinical benefit across the diabetes-related factors in THEMIS-PCI but not in the overall THEMIS population.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Leiter LA, Bhatt DL, McGuire DK, et al. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol. 2021. PMID: 33985681. doi:10.1016/j.jacc.2021.03.298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。